1. Home
  2. MNSB vs NKTX Comparison

MNSB vs NKTX Comparison

Compare MNSB & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MainStreet Bancshares Inc.

MNSB

MainStreet Bancshares Inc.

HOLD

Current Price

$22.04

Market Cap

166.4M

Sector

Finance

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.00

Market Cap

154.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNSB
NKTX
Founded
2003
2015
Country
United States
United States
Employees
204
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
166.4M
154.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MNSB
NKTX
Price
$22.04
$2.00
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$12.00
AVG Volume (30 Days)
47.0K
604.5K
Earning Date
04-20-2026
03-25-2026
Dividend Yield
1.83%
N/A
EPS Growth
N/A
11.88
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.50
N/A
Revenue Next Year
$3.77
N/A
P/E Ratio
$12.64
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.00
$1.42
52 Week High
$23.44
$2.81

Technical Indicators

Market Signals
Indicator
MNSB
NKTX
Relative Strength Index (RSI) 53.04 37.26
Support Level $21.76 $1.95
Resistance Level $22.13 $2.16
Average True Range (ATR) 0.56 0.12
MACD 0.03 -0.04
Stochastic Oscillator 73.65 9.18

Price Performance

Historical Comparison
MNSB
NKTX

About MNSB MainStreet Bancshares Inc.

MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: